Trump's Foreign Aid Retreat Guts Funding for HIV Treatments, Risking Lives Globally
Lucy Wambui first suspected she was HIV-positive in 2000, when her baby fell ill and died. At the time, treatment for the virus was too costly for many families in the Kenyan town where she lives, 120 miles from Nairobi.
'People used to sell their land to buy medicines,' she recalled. It wasn't until 2011 that she began antiviral therapy, thanks to free drugs available through the US-funded President's Emergency Plan for AIDS Relief, or Pepfar.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
16 minutes ago
In Uganda, a tougher bicycle offers hope for better health coverage in rural areas
LIRA, Uganda -- The bicycle parked in Lucy Abalo's compound doesn't belong to her. Any one of the hundreds of people in her village can show up and ask to use it. A man might wish to take his pregnant wife for a checkup. A woman might need transport to pick up HIV medication. An injured child might need a trip to a hospital. 'The goodness about this bike,' Abalo said, is its availability to all. She is one of dozens of 'village doctors' in rural Uganda who recently were supplied with the Buffalo Bicycle, so called because its steel parts are reinforced to perform in areas with bad roads. World Bicycle Relief, a Chicago-based nonprofit, promotes the Buffalo Bicycle in remote parts of Africa. It collaborates with governments, non-governmental groups and others who use the bikes to improve access to health services. In Uganda, an east African country of 45 million people, efforts to market the bicycle have focused on supporting health workers like Abalo, who visits people's homes and reports any issues to authorities. As a community health extension worker, or CHEW, she has gained the trust of villagers, who can knock on her door in emergency situations. She said she helps to look after about 8,000 people in the area. And at least twice a week, she is required to report to a government-run health center about 5 kilometers (3 miles) away and assist with triaging patients. Ugandan health authorities acknowledge that one challenge for CHEWs is transportation, part of a larger burden of poverty that can leave health facilities lacking ambulances or even gas to move them. World Bicycle Relief, operating locally as Buffalo Bicycles Uganda, has collaborated with Ugandan health authorities since 2023 to equip 331 CHEWs in two of the country's 146 districts. One is Lira, 442 kilometers (274 miles) north of the capital, Kampala. Bicycles have long been ubiquitous, and many families tend to have one. Cultural norms in northern Uganda don't prohibit women from riding. While the roads in Lira town are paved, dirt paths lead into the heart of the district where farming is the main economic activity. The Buffalo Bicycle is a recent arrival. Many have never heard of it, or can't afford it. Retailing for roughly $200, it is three times more expensive than the cheapest regular bicycle — otherwise out of reach for many CHEWs, who do not yet earn a salary. The bike's promoters cite its durability in rough terrain, needing fewer trips to the mechanic as a way to save money. The Buffalo Bicycle's heavy-gauge steel frame is so strong that it comes with a five-year warranty, said Amuza Ali, a monitoring officer in Lira for Buffalo Bicycles Uganda. Abalo and others told the AP the Buffalo Bicycle felt uncomfortable to use in the beginning, with a braking system that doesn't permit carefree backpedaling. 'When I climbed on it, it wasn't that easy as I thought,' Abalo said. 'I was like, 'I am trying again to learn how to ride.'' CHEWs using the bicycles reported a 108% increase in households reached each week, and the time to reach health facilities dropped by nearly half, according to a study published in May by World Bicycle Relief. The study shows that 'mobility is not a luxury in healthcare' but a lifeline, CEO Dave Neiswander said in a statement released for the report. Diana Atwine, permanent secretary at the Ministry of Health, has urged the distribution of bicycles to more CHEWs across Uganda, saying front-line health workers save an unknown number of lives each year. Abalo received her Buffalo Bicycle from the health minister last year. One of her neighbors, Babra Akello, said she has used the bicycle at least six times already. The first was for transport to an antenatal checkup. She praised Abalo's willingness to help. The bike has also been used for emergencies. One evening earlier this year, a neighbor's 4-year-old child suffered a deep cut while playing in the dirt. With the child's parents away, Abalo transported the bleeding boy to a facility where he briefly lost consciousness before being revived. 'That bike, not me, saved the life of that child,' Abalo said. 'If that bike hadn't been there, I don't know what would have happened.'
Bloomberg
4 hours ago
- Bloomberg
UNAIDS Executive Director: ‘The HIV Response Is in Crisis'
Winnie Byanyima says her organization has lost almost 50% of its funding, a gap that is undermining global efforts to combat HIV/AIDS. By Are we unraveling years of progress on fighting HIV/AIDS? For the past two decades, the US has led the global response to a virus and disease that have together claimed more than 40 million lives. But there are still more than a million new infections every year; with no vaccine or cure, preventing further spread is critical. This is why there was so much alarm from campaigners and experts when the US Department of Government Efficiency, led by Elon Musk, started slashing foreign aid. In an interview last month, Musk himself told me that HIV-prevention programs were ongoing. But Winnie Byanyima, executive director of the Joint United Nations Programme on HIV and AIDS, tells a different story. Her organization is one of the key bodies fighting the virus globally — UNAIDS operates in nearly 100 countries — and Byanyima says the disruption she's seeing is both real and deadly. We spoke while Byanyima was on a visit to South Africa, where the rollout of one of the most promising HIV-prevention tools in a generation is now in doubt. 'Even if I get the next batch of medicines,' one aid worker in Soweto told her, 'they may expire because the two people I had who go out and reach people in their communities [are no longer there].' This interview has been edited for length and clarity. First of all, are you able to set the record straight? To what extent has your work at UNAIDS been affected by the DOGE-led cuts to USAID? First, globally, the HIV response is in crisis. Clinics have closed. Prevention services have halted. People are losing access to lifesaving medicines. People are scared. Our work as the UN leader of the global HIV response is also affected severely. We've lost close to 50% of our funding. It came from two pockets of the United States government. So we are also struggling to stay alive. But there is a crisis and a huge disruption, the biggest since the global response was created about 25 years ago. I know that Elon Musk has doubted that these disruptions are there,[and] has even said that if they are there, he would fix them. 1 I know he has left government, but I'll be happy to go with him anywhere in Africa or Asia to show him, or take any other American official to see what the real impacts are for people living with HIV and for people at risk of HIV, like gay men [or] women and girls in Africa. In our May conversation, Musk said he did not believe many HIV-prevention programs had stalled: 'If in fact this is true, which I doubt it is, then we'll fix it.' But he also questioned the assertion that cutting USAID would result in any fatalities, saying that recipient organizations 'don't even try to come up with a show orphan' to back up their claims of saving lives. When you say the HIV response globally is in crisis, how much of that is to do with US funding cuts? How great is America 's responsibility for that situation? Huge. The United States government and US taxpayers were contributing a lion's share of the support to developing countries to fight this disease, up to 73%. You might say, why the United States? Well, it's the wealthiest country in the world, and these are the poorest countries in the world. By pulling its funding away very quickly, the US didn't [give] these highly indebted countries — that are heavily impacted by [the] climate crisis, that have huge burdens of disease beyond HIV — enough time to be able to fill the gap. 2 UNAIDS created a portal to track the real-time effects of US funding cuts in the developing countries in which it operates, including observations from officials in the field. 'My greatest fear is that we will return to the dark days of the epidemic,' says the director of UNAIDS in Zambia. But what about other donors? What about rich countries in the Middle East or other G-7 countries or philanthropists with deep pockets? There have been two main sources of funding to support developing countries [on HIV/AIDS]. One is the American program, PEPFAR, the presidential initiative, and the other is called the Global Fund, where other donors — the Europeans, the Japanese, the Chinese — all put money together and help the developing countries. When the major contributor pulls out with little notice, things collapse. That is what has happened. In South Africa, which funds 80% of its own response and has been getting US support for only 17%, I visited a clinic in Soweto and saw the impact. A man who works [there] told me, 'Even if I get the next batch of medicines, they may expire because the two people I had who go out and reach people in their communities and bring them for service [are no longer there].' He's seeing a drop in the numbers of people coming forward to get what they need to prevent or to be treated. 3 This is backed up by recent Bloomberg reporting from South Africa, which has the world's largest HIV-treatment program with 80% of 7.8 million infected people on medication. So we are seeing that even in a country that's not so dependent, there are disruptions. Even in a country where the will is so strong, like South Africa, you're still seeing a gap that is definitely going to result in more new infections and more deaths. We know from our modeling that if the gap is not filled by other funding, in the next four years we are going to see up to 6.6 million additional new infections and additional deaths of 4.2 million. And that's in addition to what we were already estimating. PEPFAR, the program that you are referring to, 4 is the responsibility of the State Department. Marco Rubio, the Secretary of State, says 85% of PEPFAR is functional. PEPFAR stands for the President's Emergency Plan for AIDS Relief. It was a US policy choice that began during the George W. Bush administration in 2003, and has since then provided cumulative funding of $120 billion for HIV/AIDS treatment. That's roughly as much as the US government spends on its Supplemental Nutrition Assistance Program (food stamps) in a single year. It isn't exactly that because the PEPFAR program on the ground is implemented by two parts of the American government, the CDC [Centers for Disease Control and Prevention] in Atlanta and USAID. Now USAID has been shut. So there's no work that was done by USAID that's going on right now, though some work by the CDC is still going on. 'I say to President Trump: You are a man who likes to do a deal. Here's a deal.' But over and above that, there has been confusion. First, the cut was a stop-work order for everything. Then, within a week — and we thank the American administration for realizing that this was going to cost lives — they said it can come back, but only some of it. We see testing and treatment coming back by the CDC. We don't see much progress on prevention. So in many places, prevention clinics where people get their condoms, their PrEP, vaginal ring, whatever — these are not open. So we do see many gaps, particularly for women and girls in Africa, gay men, sex workers and people who inject drugs. They have their special clinics; those too have closed. It seems then that you think the statement '85% of PEPFAR is functional' is inaccurate, or misleading. It is inaccurate to the extent that the impact for the very low-income countries is huge. Our own data shows us that the impact is much bigger than that. 5 We asked the State Department to respond to UNAIDS' assertion that many HIV-prevention programs supported by the US have stalled. They told us they continue to support testing, care, treatment and prevention of mother-to-child transmission, and that an estimated 85% of beneficiaries could be receiving lifesaving treatment and prevention of mother-to-child transmission. All other PEPFAR-funded services are under review. Did you have any contact with Elon Musk's team at DOGE? We appealed to him publicly. I am very loud on social media and said I'm happy to meet him and take him to see. Anyway, he's left government. We are addressing ourselves now to the American government to say, 'You started something strong.' A Republican government, President Bush, came out at a time of the worst pandemic of the century and [began] a program to save lives. Right now, there are tools that could end this pandemic, and I say to President Trump: You are a man who likes to do a deal. Here's a deal. There is an American innovation called lenacapavir that's 100% effective to stop infections. An American innovation that creates American jobs that could be rolled out and we could cut down new infections almost to zero. Why not do this? That would be another Republican president bringing a revolution on prevention. This could be a win-win. Get the Bloomberg Weekend newsletter. Big ideas and open questions in the fascinating places where finance, life and culture meet. Sign Up By continuing, I agree to the Privacy Policy and Terms of Service. It is a US pharmaceutical company, Gilead, that's behind lenacapavir, which has been through lots of trials. But there would still be an issue, wouldn't there? It is likely to be extremely expensive. Wouldn't access to the drug possibly be like antiretrovirals in their early years, when they were out of the reach of the world's poorest people? You are right. We are hearing rumors in the media of $25,000 per person per year, and [if] it comes out at that price, then it will not bring new infections down to zero. 6 When they first came out, antiretrovirals used to treat HIV infections could cost more than $10,000 a year, but they eventually became widely available thanks to the work of aid organizations. Now lencapavir promises to provide six-month protection from infection, eliminating the need to take daily pills. On June 18, Gilead said that lenacapavir, marketed as Yeztugo, has a list price of $28,218 per year. It sounds as if this has been an extraordinary rollercoaster. You had immense hope that 2025 could be a breakthrough year, and instead you spent the first half of it almost battling for the organization's survival? That's true. I'm letting people go. People who have, over 20 years, built the experience to support this response. It's sad and it's unnecessary considering the billions that are being spent on building up new weapons systems and fighting wars. My core budget was not even $150 million [a year], but now it's been slashed by almost half. It's a sad moment, but we won't give up. I'm inspired by the governments and the people in countries [that] aren't giving up. They are stretching themselves, volunteering, doing things differently. We've got to keep people alive. So we are pushing on. We will continue fighting. I read that you are having to fight on another front at this moment, a personal front. You grew up in Uganda, you served your country as a political leader before you moved into international work, 7 and your husband is a longtime opposition leader in Uganda. Is it the case that he remains imprisoned, as we speak, on very serious charges? Byanyima has had quite a career. She was a flight engineer for Uganda Airlines, a combatant (alongside her husband) in the National Resistance Army and Uganda's ambassador to France from 1989 until 1994. She helped draft Uganda's 1995 constitution, and served two consecutive terms as a member of parliament before serving in leadership roles at the African Union and Oxfam International. She became executive director of UNAIDS in August 2019. That is true, Mishal. My country has struggled through crises since independence. We thought we had turned the corner through a revolution that brought back democracy, but we've seen reversals in the last 10 to 15 years. My husband has been an opposition leader for the last 25 years. But for most of those, he's been in and out of jail — always criminalized, but always being exonerated by the courts. Last November he was abducted from neighboring Kenya and taken across the border. It's now six months he's been in jail. He hasn't been tried. For a long time he was not even charged, he was just illegally being held. He's not the only political prisoner, but we have the international human rights organizations supporting his cause, supporting that he should be released on bail, so that he can fight whatever charge they may have against him. 8 In February, Byanyima's husband Kizza Besigye was charged with treason over an alleged plot to overthrow Ugandan President Yoweri Museveni. Besigye has unsuccessfully tried to unseat Museveni — who has been in power since 1986 — in four elections. How is he and are you able to be in contact with him? We are in contact with him and able to visit him. But he's not in a good condition. He's in a tiny cell where you can hardly even sit by his bedside, there's not enough room. So yes, I am angry at how he's being treated. I'm angry at the illegality that the president has shown. The Supreme Court decided that as a civilian, he should not be tried by the military. [President Yoweri Museveni] reversed it by bringing a law before Parliament to allow civilians to be tried by the military. 'No one anywhere — in any country in the world, rich or poor — should take freedom for granted, should assume that because they're enjoying human rights, because there's rule of law at a certain point in time, that it'll always be there.' Didn't he used to be a friend of yours, President Museveni? He is a family friend. I first met him when I was little. He was always in and out of the family home. He was a friend of my parents. This is just about politics and power. President Museveni has never quite accepted the idea of being a democratically elected leader who respects an opposition and competes with them fairly. I wonder what this leads you to conclude about the nature of power and authority. Your generation knows what dictatorship was like when you were growing up, the time of Idi Amin. You ended up having to leave Uganda, you came back, and you were part of building institutional governance. What are the lessons of how to build a nation to ensure structures that safeguard people's rights? You raise a very important point. No one anywhere — in any country in the world, rich or poor — should take freedom for granted, should assume that because they're enjoying human rights, because there's rule of law at a certain point in time, that it'll always be there. You can have reversals. Sudden reversals or slow reversals, but reversals do happen. You must always be working as a citizen, doing your duty to protect your constitution, to defend the rule of law, to defend the human rights of others, not just for yourself. May I close, Winnie, by asking you what gives you strength? To be battling on these two fronts — one professional, one personal — at the same time, it would take a lot out of anyone. It is tough, but the truth is that I have lived a life of struggle. I don't say my life was always rough. I've had, and I still have, very many happy moments. But at every point I have had to be a part of struggles, to make lives better — for myself and for others. What's happening to me on the personal front, what's happening on the professional side, I see them all as a struggle for justice. Justice for my husband, justice for people living with HIV, justice for those who are denied their rights because of their sexual orientation, because of who they are. So I live day by day and think everybody has their load to carry. And that's mine. Mishal Husain is Editor at Large for Bloomberg Weekend. More On Bloomberg
Yahoo
4 hours ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
